TP53 and diffuse large B-cell lymphoma: In summary, our research affirms that p53/PD-L1 co-expression in patients with DLBCL displays a significant adverse prognostic influence, and that the clinical outcome of this cohort cannot be necessarily improved by incorporating Rituximab into chemotherapy treatment.